• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ALEC

    Alector Inc.

    Subscribe to $ALEC
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.

    IPO Year: 2019

    Exchange: NASDAQ

    Website: alector.com

    Peers

    $ANNX
    $PASG

    Recent Analyst Ratings for Alector Inc.

    DatePrice TargetRatingAnalyst
    12/17/2024$9.00 → $2.50Outperform → Neutral
    Mizuho
    12/16/2024$4.00Buy → Hold
    Stifel
    12/4/2024$9.00 → $1.00Neutral → Underperform
    BofA Securities
    11/29/2024$35.00 → $7.00Buy
    H.C. Wainwright
    11/26/2024$10.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    12/14/2023$8.00 → $15.00Hold → Buy
    Stifel
    12/12/2023$12.00Buy
    Deutsche Bank
    9/25/2023$4.00Sell
    Goldman
    9/22/2023$13.00Overweight
    Cantor Fitzgerald
    1/6/2023$24.00 → $12.00Buy → Neutral
    BofA Securities
    See more ratings

    Alector Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alector Reports First Quarter 2025 Financial Results and Provides Business Update

      Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, toda

      5/8/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Participate in Upcoming Healthcare Conferences

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, New York) Tuesday, May 20, 2025, at 12:00 p.m. ET, fireside chat A webcast of each conference presentation will be available on the "Events & Presentations" page w

      5/6/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

      --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational hum

      4/17/25 8:00:00 AM ET
      $ALEC
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Alector Provides Executive Leadership Update

      --Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Gary Romano, M.D., Ph.D., has made the decision to step down from his role as Chief Medical Officer. Dr. Romano will continue to contribute to the company as an advisor following his transition. Giacomo Salvadore, M.D., has been appointed Chief Medical Officer effective April 25, 2025. Dr. Salvadore is a

      3/28/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company

      2/26/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Participate in Upcoming Healthcare Conferences

      SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference (Boston, Massachusetts) Tuesday, March 4, 2025, at 9:10 a.m. ET, corporate presentation Leerink Partners Global Biopharma Conference (Miami, Florida) Tuesday, March 11, 2025, at 8:40 a.m. ET, corporate presentation Stifel 2025 Virtual CNS Forum Tuesday, March 18, 2025, at 2:00 p.m. ET, corporate presentation

      2/25/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

      SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2024, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and follo

      2/19/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

      Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Completion of enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease anticipated in mid-2025, with approximately 75% target recruitment achieved $457.2 million in cash, cash equivalents and investments as of September 30, 2024, expected to fund operations through 2026 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLO

      1/13/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

      SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of

      11/25/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

      SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE:HTGC) for up to $50 million. "Alector is in a strong cash position with more than $457 million in cash and investments. This credit facility further enhances our financial strength and provides the Company with increased strategic and operational flexibility," said Marc Grasso, M.D., Chief Financial Officer of Alector. "We anticipate transformational data from both the AL002 INVOKE-2 Phase 2 trial and the latozinemab INFRO

      11/14/24 4:05:46 PM ET
      $ALEC
      $HTGC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance

    Alector Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Alector Inc.

      10-Q - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:15:17 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Alector, Inc. (0001653087) (Filer)

      5/8/25 4:10:08 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Alector Inc.

      DEFA14A - Alector, Inc. (0001653087) (Filer)

      4/24/25 4:02:03 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Alector Inc.

      DEF 14A - Alector, Inc. (0001653087) (Filer)

      4/24/25 4:01:14 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.

      SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)

      4/17/25 9:35:32 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Inc. filed SEC Form 8-K: Leadership Update

      8-K - Alector, Inc. (0001653087) (Filer)

      3/28/25 4:05:08 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Alector Inc.

      8-K - Alector, Inc. (0001653087) (Filer)

      3/10/25 9:01:07 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Alector Inc.

      S-8 - Alector, Inc. (0001653087) (Filer)

      2/26/25 4:20:13 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Alector Inc.

      10-K - Alector, Inc. (0001653087) (Filer)

      2/26/25 4:15:35 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Alector, Inc. (0001653087) (Filer)

      2/26/25 4:10:08 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Alector Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Alector Inc.

      SC 13G - Alector, Inc. (0001653087) (Subject)

      12/6/24 5:30:28 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/12/24 7:21:57 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Alector Inc.

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      11/7/24 12:41:31 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Alector Inc. (Amendment)

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      2/13/24 4:59:03 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Alector Inc.

      SC 13G - Alector, Inc. (0001653087) (Subject)

      2/12/24 10:03:52 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Alector Inc. (Amendment)

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      2/9/24 4:48:56 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Alector Inc. (Amendment)

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      2/9/24 8:35:57 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Alector Inc.

      SC 13G - Alector, Inc. (0001653087) (Subject)

      2/8/24 6:59:02 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Alector Inc. (Amendment)

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      1/24/24 2:27:18 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Alector Inc. (Amendment)

      SC 13G/A - Alector, Inc. (0001653087) (Subject)

      10/13/23 4:01:12 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Alector Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scheller Richard H was granted 15,833 shares, increasing direct ownership by 31% to 66,666 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      5/2/25 6:00:09 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Grasso Marc sold $26,547 worth of shares (18,091 units at $1.47), decreasing direct ownership by 5% to 312,560 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:13 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Rosenthal Arnon sold $59,176 worth of shares (40,330 units at $1.47), decreasing direct ownership by 2% to 2,466,744 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:18 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and Head of R&D Kenkare-Mitra Sara sold $42,662 worth of shares (29,073 units at $1.47), decreasing direct ownership by 5% to 536,142 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:24 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Romano Gary sold $23,927 worth of shares (16,306 units at $1.47), decreasing direct ownership by 5% to 332,977 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      3/5/25 4:05:05 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and Head of R&D Kenkare-Mitra Sara sold $66,764 worth of shares (26,500 units at $2.52), decreasing direct ownership by 4% to 565,215 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      12/3/24 5:40:03 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Grasso Marc sold $41,542 worth of shares (16,489 units at $2.52), decreasing direct ownership by 5% to 330,651 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      12/3/24 5:40:06 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Rosenthal Arnon sold $131,442 worth of shares (52,172 units at $2.52), decreasing direct ownership by 2% to 2,507,074 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      12/3/24 5:40:05 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Romano Gary sold $37,519 worth of shares (14,892 units at $2.52), decreasing direct ownership by 4% to 349,283 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      12/3/24 5:40:03 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Scheller Richard H was granted 15,833 shares, increasing direct ownership by 45% to 50,833 units (SEC Form 4)

      4 - Alector, Inc. (0001653087) (Issuer)

      10/10/24 4:05:06 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Alector Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Alector Reports First Quarter 2024 Financial Results and Provides Business Update

      Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202

      5/8/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea

      3/29/22 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. 

      2/7/22 8:30:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development

      SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development. In this newly created role, Dr. Kenkare-Mitra will lead all aspects of the company's immuno-neurology and oncology R&D efforts, including oversight of the research, development, clinical, manufacturing, regulatory, and related functions. Dr. Kenkare-Mitra will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. Dr. Kenkare-Mitra joins Alector from Genentech where, as Senior Vice President, Development S

      12/15/21 8:30:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Company's Board of Directors. Dr. Garofalo is a veteran biopharmaceutical executive with more than 25 years of experience in global clinical development and regulatory affairs, with a focus on neurology. "Betsy is a highly-regarded leader with unmatched clinical development experience, particularly in neurodegenerative disease indications. As we advance our pipeline of novel immuno-neurology therapeutics into later-stage clinical trials, her expert perspec

      9/28/21 8:30:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Alector Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alector downgraded by Mizuho with a new price target

      Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $2.50 from $9.00 previously

      12/17/24 7:23:27 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by Stifel with a new price target

      Stifel downgraded Alector from Buy to Hold and set a new price target of $4.00

      12/16/24 6:41:43 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by BofA Securities with a new price target

      BofA Securities downgraded Alector from Neutral to Underperform and set a new price target of $1.00 from $9.00 previously

      12/4/24 7:19:54 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright reiterated coverage on Alector with a new price target

      H.C. Wainwright reiterated coverage of Alector with a rating of Buy and set a new price target of $7.00 from $35.00 previously

      11/29/24 8:14:08 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Alector from Equal-Weight to Underweight and set a new price target of $3.00 from $10.00 previously

      11/26/24 8:14:38 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector upgraded by Stifel with a new price target

      Stifel upgraded Alector from Hold to Buy and set a new price target of $15.00 from $8.00 previously

      12/14/23 6:47:44 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Alector with a new price target

      Deutsche Bank initiated coverage of Alector with a rating of Buy and set a new price target of $12.00

      12/12/23 6:47:04 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Alector with a new price target

      Goldman initiated coverage of Alector with a rating of Sell and set a new price target of $4.00

      9/25/23 7:36:19 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Alector with a new price target

      Cantor Fitzgerald initiated coverage of Alector with a rating of Overweight and set a new price target of $13.00

      9/22/23 7:14:11 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector downgraded by BofA Securities with a new price target

      BofA Securities downgraded Alector from Buy to Neutral and set a new price target of $12.00 from $24.00 previously

      1/6/23 12:46:54 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Alector Inc. Financials

    Live finance-specific insights

    See more
    • Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company

      2/26/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

      SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2024, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and follo

      2/19/25 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

      Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Completion of enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease anticipated in mid-2025, with approximately 75% target recruitment achieved $457.2 million in cash, cash equivalents and investments as of September 30, 2024, expected to fund operations through 2026 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLO

      1/13/25 8:00:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

      SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of

      11/25/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

      Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024 Patient baseline characteristics data for the INVOKE-2 trial confirm the intended study population for testing the effects of AL002, a novel TREM2 agonist, in early AD The latozinemab pivotal INFRONT-3 Phase 3 trial continues to progress well, supported by a recent U.S. Food and Drug Administration interaction post Breakthrough Therapy Designation $503.3 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEW

      8/7/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Host Mid-Year Earnings Conference Call

      SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2024, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events, and following the event, a replay will be archived there for 30 days. Interested parties

      7/31/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

      Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023 First participant in the global PROGRESS-AD Phase 2 clinical trial of AL101 in early AD dosed in Q1 2024 Latozinemab granted FDA's Breakthrough Therapy Designation for frontotemporal dementia due to a mutation in the progranulin gene (FTD-GRN) Achieved target enrollment in pivotal INFRONT-3 latozinemab Phase 3 trial in FTD-GRN during Q4 2023 $620.0 million in cash, cash equivalents and investments after January 2024 equity offering anticipated to provide runway through 2026 Management to host conference c

      2/27/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

      SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2023, and provide a full-year business update. A press release detailing fourth quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested partie

      2/20/24 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector Reports Second Quarter 2023 Financial Results and Provides Business Update

      Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer's disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 Presented update on INVOKE-2 at the Alzheimer's Association International Conference (AAIC) Anticipate completing enrollment in pivotal INFRONT-3 trial of latozinemab with symptomatic FTD-GRN participants in Q4 2023 based on recent interactions with the FDA and EMA $630.0 million in cash, cash equivalents and investments provide runway through 2025;  revenue and expense guidance updated for 2023 Management to host conference call and we

      8/3/23 4:05:00 PM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alector to Host Mid-Year Earnings Conference Call

      SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Thursday, August 3, 2023, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2023, and provide a mid-year business update. A press release detailing second quarter results will be issued prior to the call. The event will be webcast live under the investor relations section of Alector's website at https://investors.alector.com/events-and-presentations/events and following the event a replay will be archived there for 30 days. Interested parties parti

      7/27/23 8:30:00 AM ET
      $ALEC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care